Larvol Delta - Viracta-Therapeutics-Announces-Reprioritization-of-Resources-to-Enhance-Focus-on-Nanaval-Development-Program-in-Patients-with-Relapsed-or-Refractory-EBVPositive-Peripheral-TCell-Lymphoma

Valcyte (valganciclovir) - Roche, Mitsubishi Tanabe

nanatinostat (VRx-3996) - Viracta Therap

https://www.globenewswire.com/news-release/2024/11/06/2976142/0/en/Viracta-Therapeutics-Announces-Reprioritization-of-Resources-to-Enhance-Focus-on-Nana-val-Development-Program-in-Patients-with-Relapsed-or-Refractory-EBV-Positive-Peripheral-T-Cell.html

Nov 6, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next